Vytrus Biotech (VYT.MC) Stock Price

Vytrus Biotech Price

🇪🇸CLOSED
17.95EUR
Market closed
Today +/-
Today %

Vytrus Biotech (VYT.MC) Stock | ISIN ES0105618005 | WKN A3DHK4. The current Vytrus Biotech stock price is 17.95 EUR (2026). Revenue is 8.53 M EUR. Net income is 2.62 M EUR. The P/E ratio is 51.79. Market capitalization is 137.14 M EUR. Vytrus Biotech operates in the Non-cyclical consumption sector.

Revenue has compounded at 33.6% per year over the past 6 years to 5.05 M EUR. Earnings per share have grown at 45.1% per year over the last 4 years. Vytrus Biotech's net margin stands at 20.2%, up from 12.7% several years earlier.

Vytrus Biotech stock price

Details

Stock Price

How to Read This Chart

This chart tracks the historical stock price of Vytrus Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Vytrus Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Vytrus Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Vytrus Biotech Stock Price History
DateVytrus Biotech Price
Access this data via the Eulerpool API

Vytrus Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2018
887,800 EUR
-156,800 EUR
-43,900 EUR
Jan 1, 2019
1.22 M EUR
-158,000 EUR
-72,700 EUR
Jan 1, 2020
1.7 M EUR
166,600 EUR
216,900 EUR
Jan 1, 2021
2.8 M EUR
429,500 EUR
450,000 EUR
Jan 1, 2022
3.68 M EUR
635,600 EUR
605,300 EUR
Jan 1, 2023
3.74 M EUR
432,500 EUR
545,000 EUR
Jan 1, 2024
5.05 M EUR
1.01 M EUR
1.02 M EUR
Invalid Date
7.09 M EUR
2.03 M EUR
1.9 M EUR
Invalid Date
8.53 M EUR
3 M EUR
2.62 M EUR
Invalid Date
10.2 M EUR
3.91 M EUR
3.31 M EUR
Invalid Date
15.45 M EUR
6.56 M EUR
5.49 M EUR

Vytrus Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Jun 27, 2026, 10:05 AM
 
REVENUE (M EUR)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (M EUR)
NET INCOME (M EUR)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
20212022202320242025e2026e2027e2028e
2335781015
1005066.674014.292550
1001001008057.14504026.67
23344444
00011235
1005066.67
6.936.846.747.557.557.557.557.55
Details

Income Statement Key Figures

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Vytrus Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Vytrus Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Vytrus Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Vytrus Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Vytrus Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Vytrus Biotech stock margins

The Vytrus Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vytrus Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vytrus Biotech.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2018
132.03 %
-17.66 %
-4.94 %
Jan 1, 2019
129.22 %
-12.93 %
-5.95 %
Jan 1, 2020
87.81 %
9.77 %
12.72 %
Jan 1, 2021
84.91 %
15.31 %
16.05 %
Jan 1, 2022
82.33 %
17.26 %
16.44 %
Jan 1, 2023
83.62 %
11.57 %
14.58 %
Jan 1, 2024
82.11 %
20.09 %
20.24 %
Invalid Date
82.11 %
28.68 %
26.85 %
Invalid Date
82.11 %
35.15 %
30.69 %
Invalid Date
82.11 %
38.35 %
32.46 %

Vytrus Biotech Stock Revenue, EBIT, Earnings per Share

The Vytrus Biotech earnings per share therefore indicates how much revenue Vytrus Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2018
0.12 EUR
-0.02 EUR
-0.01 EUR
Jan 1, 2019
0.17 EUR
-0.02 EUR
-0.01 EUR
Jan 1, 2020
0.24 EUR
0.02 EUR
0.03 EUR
Jan 1, 2021
0.4 EUR
0.06 EUR
0.06 EUR
Jan 1, 2022
0.54 EUR
0.09 EUR
0.09 EUR
Jan 1, 2023
0.55 EUR
0.06 EUR
0.08 EUR
Jan 1, 2024
0.67 EUR
0.13 EUR
0.14 EUR
Invalid Date
0.93 EUR
0.27 EUR
0.25 EUR
Invalid Date
1.12 EUR
0.4 EUR
0.34 EUR
Invalid Date
1.34 EUR
0.52 EUR
0.43 EUR

Vytrus Biotech business model & stock analysis

Vytrus Biotech SA is a biotechnology company, which engages in the development of cosmetic active ingredients from plant stem cell technology. The company is headquartered in Terrassa, Barcelona and currently employs 29 full-time employees. The company went IPO on 2022-03-24. The firm develops high added value natural active ingredients on an industrial scale and provides ingredients and recombinant proteins for its use in the cosmetics and pharmaceutical sectors. The Company’s technology is based on using plant cell cultures to produce bioactive molecules. The firm obtains plant cells, known as Plant Stem Cell technology, which is applicable for cosmetics. Vytrus Biotech specifically target dermo-cosmetics as well as veterinary medicine, functional food and other pharmaceuticals, generating savings of more than 99% in natural resources.

Vytrus Biotech Eulerpool Fair Value

Vytrus Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Vytrus Biotech annual returns

Details

Annual Return

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Vytrus Biotech shares outstanding

The number of shares was Vytrus Biotech in 2025 — This indicates how many shares 7.555 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.
  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2018
7.12 M base_Shares
Jan 1, 2019
7.12 M base_Shares
Jan 1, 2020
7.12 M base_Shares
Jan 1, 2021
6.93 M base_Shares
Jan 1, 2022
6.84 M base_Shares
Jan 1, 2023
6.74 M base_Shares
Jan 1, 2024
7.55 M base_Shares
Invalid Date
7.55 M base_Shares
Invalid Date
7.55 M base_Shares
Invalid Date
7.55 M base_Shares
Price targets and forecasts for Vytrus Biotech are not yet available.

Vytrus Biotech shareholder structure

% Name
16.9791%
Exposito Tarres (Oscar)
Exposito Tarres (Oscar)
16.9791%
Jane Font (Albert)
Jane Font (Albert)
8.47455%
Zamit Capital SCA SICAV RAIF
Zamit Capital SCA SICAV RAIF
6.52581%
Boyser, S.L.
Boyser, S.L.
5.58641%
Icf Venture Tech II Fcre
Icf Venture Tech II Fcre
5.36656%
Julia Patrimoni Sl
Julia Patrimoni Sl
4.99679%
Barnet Products LLC
Barnet Products LLC
0.69302%
Andbank Wealth Management, SGIIC, S.A.U.
Andbank Wealth Management, SGIIC, S.A.U.
0.65445%
Auriga Global Investors Sociedad de Valores, S.A.
Auriga Global Investors Sociedad de Valores, S.A.
0.33987%
Renta 4 Gestora, S.G.I.I.C., S.A.
Renta 4 Gestora, S.G.I.I.C., S.A.

Vytrus Biotech Executives and Management Board

DF

Don Albert Jane Font

Founding Partner, Executive Chairman of the Board, Chief Executive Officer, Chief Operating Officer · since 2021

OT

Dr. Oscar Exposito Tarres

Founding Partner, Chief Executive Officer, Chief Scientific Officer, Executive Director · since 2009

DM

Don Jordi Rovira Martinez

Chief Financial Officer, Non-Member Secretary of the Board

DG

Don Manel Lopez Galvan

Chief Operating Officer · since 2024

DL

Dna. Sara Laplana Lasierra

Executive Chief Scientific Officer

Vytrus Biotech Supply Chain

Frequently asked questions about Vytrus Biotech

All fundamentals and in-depth analysis of Vytrus Biotech

Our stock analysis for Vytrus Biotech Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vytrus Biotech Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.